Surgical indications, methods and perioperative management of ulcerative colitis

doi:10.3877/cma.j.issn.2095-3224.2020.01.015

Abstract

Abstract:

Ulcerative colitis is a manifestation of inflammatory bowel disease (IBD). The incidence of ulcerative colitis is mainly concentrated in the colon and rectum. Its complications are mainly hemorrhage, perforation, canceration and recurrence of obstruction. Ulcerative colitis is different from Crohn′s disease. Ulcerative colitis can be cured by operation, and the recurrence rate and complication rate after operation are low. Patients with ulcerative colitis have more important significance. The indications for surgery, the management of the operation and the management of the perioperative period have a close relationship with the effect of the operation and the life quality of the postoperative patients. Therefore, the surgeon′s experience and technology put forward higher requirements. This paper focuses on the surgical indications, surgical methods and perioperative management of ulcerative colitis.

Key words: Ulcerative colitis, Operative indications, Operative methods, Perioperative management

Rui Zhao, Yong Zhou. Surgical indications, methods and perioperative management of ulcerative colitis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(01): 76-79.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.01.015

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I01/76

References 52

[1]	Loddo I, Romano C. Inflammatory Bowel Disease: Genetsics, Epigenetsics, and Pathogenesis [J]. Frontiers in Immunology, 2015, 6: 551.
[2]	Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: The emerging role of epigenetics [J]. Gastroenterology, 2013, 145(2): 293-308.
[3]	Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation [J]. Nature Medicine, 2010, 16(1): 90-97.
[4]	McLeod RS. Surgery for inflammatory bowel diseases [J]. Digestive Diseases, 2003, 21(2): 168-179.
[5]	Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and Meta-analysis of population-based studies [J]. Gastroenterology, 2013, 145(5): 996-1006.
[6]	Bohl JL, Sobba K. Indications and options for surgery in ulcerative colitis [J]. Surgical Clinics of North America, 2015, 95(6): 1211-1232.
[7]	Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis [J]. Gut, 1992, 33(7): 938-941.
[8]	Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn′s disease of the colon [J]. Inflammatory Bowel Diseases, 2009, 15(4): 630-638.
[9]	Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: Clinical guidelines and rationale-Update based on new evidence [J]. Gastroenterology, 2003, 124(2): 544-560.
[10]	Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis [J]. Diseases of the Colon & Rectum, 2005, 48(11): 1997-2009.
[11]	Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis [J]. Diseases of the Colon & Rectum, 2014, 57(1): 5-22.
[12]	Reiser JR, Waye JD, Janowitz HD, et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy [J]. American Journal of Gastroenterology, 1994, 89(1): 119-122.
[13]	Dignass A, Preiss JC, Aust DE, et al. Updated german guideline on diagnosis and treatment of ulcerative colitis, 2011 [J]. Zeitschrift Fur Gastroenterologie, 2011, 49(9): 1276-1341.
[14]	Dayan B, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy [J]. World Journal of Gastroenterology, 2012, 18(29): 3833-3838.
[15]	Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management [J]. American Journal of Gastroenterology, 2003, 98(11): 2363-2371.
[16]	Juviler A, Hyman N. Ulcerative colitis: the fate of the retained rectum [J]. Clinics in Colon and Rectal Surgery, 2004, 17(1): 29-34.
[17]	Lee-Kong S, Kiran RP. Ongoing challenges and controversies in ulcerative colitis surgery [J]. Expert Review of Gastroenterology & Hepatology, 2016, 10(2): 187-191.
[18]	Bellolio RF, Zuniga AJ, Wagner HP, et al. Ileorectal anastomosis in the surgical treatment of ulcerative colitis: Long-term results [J]. Revista Medica De Chile, 2008, 136(9): 1121-1126.
[19]	Paoluzi OA, Di Paolo MC, Ricci F, et al. Ileo-rectal anastomosis in ulcerative colitis: results of a long-term follow-up study [J]. Italian Journal of Gastroenterology, 1994, 26(8): 392-397.
[20]	da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis [J]. British Journal of Surgery, 2010, 97(1): 65-69.
[21]	Wibmer AG, Kroesen AJ, Grone J, et al. Predictors of permanent ileostomy after restorative proctocolectomy [J]. British Journal of Surgery, 2010, 97(10): 1561-1566.
[22]	Burns EM, Bottle A, Aylin P, et al. Volume analysis of outcome following restorative proctocolectomy [J]. British Journal of Surgery, 2011, 98(3): 408-417.
[23]	Fichera A, Silvestri MT, Hurst RD, et al. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: A comparative observational study on long-term functional results [J]. Journal of Gastrointestinal Surgery, 2009, 13(3): 526-532.
[24]	Ahmed Ali U, Keus F, Heikens JT, et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis [J]. Cochrane Database of Systematic Reviews, 2009: CD006267.
[25]	Larson DW, Davies MM, Dozois EJ, et al. Sexual function, body image, and quality of life after laparoscopic and open ileal pouch-anal anastomosis [J]. Diseases Of the Colon & Rectum, 2008, 51(4): 392-396.
[26]	El-Gazzaz GS, Kiran RP, Remzi FH, et al. Outcomes for case-matched laparoscopically assisted versus open restorative proctocolectomy [J]. British Journal of Surgery, 2009, 96(5): 522-526.
[27]	Alves A, Panis Y, Bouhnik Y, et al. Subtotal colectomy for severe acute colitis: A 20-year experience of a tertiary care center with an aggressive and early surgical policy [J]. Journal of the American College of Surgeons, 2003, 197(3): 379-385.
[28]	Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease [J]. Diseases of the Colon & Rectum, 2005, 48(1): 70-73.
[29]	Marceau C, Alves A, Ouaissi M, et al. Laparoscopic subtotal colectomy for acute for severe colitis complicating inflammatory bowel disease: A case-matched study in 88 patients [J]. Surgery, 2007, 141(5): 640-644.
[30]	Telem DA, Vine AJ, Swain G, et al. Laparoscopic subtotal colectomy for medically refractory ulcerative colitis: the time has come [J]. Surgical Endoscopy And Other Interventional Techniques, 2010, 24(7): 1616-1620.
[31]	Cahill RA, Lindsey I, Jones O, et al. Single-port laparoscopic total colectomy for medically uncontrolled colitis [J]. Diseases of the Colon & Rectum, 2010, 53(8): 1143-1147.
[32]	Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery [J]. Annals of Surgery, 2015, 261(3): 487-496.
[33]	Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis [J]. Journal of the American College of Surgeons, 2007, 204(5): 956-962.
[34]	Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications [J]. Journal of Gastrointestinal Surgery, 2008, 12(10): 1730-1736.
[35]	Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNF treatment and post-operative complications in patients with inflammatory bowel disease [J]. Alimentary Pharmacology & Therapeutics, 2013, 37(11): 1057-1064.
[36]	Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients [J]. Molecular Nutrition & Food Research, 2008, 52(8): 867-874.
[37]	Salinas H, Dursun A, Konstantinidis I, et al. Does preoperative total parenteral nutrition in patients with ulcerative colitis produce better outcomes [J]. International Journal of Colorectal Disease, 2012, 27(11): 1479-1483.
[38]	Weimann A, Braga M, Harsanyi L, et al. ESPEN guidelines on enteral nutrition: Surgery including organ transplantation [J]. Clinical Nutrition, 2006, 25(2): 224-244.
[39]	Royall D, Greenberg GR, Allard JP, et al. Total enteral nutrition support improves body composition of patients with active Crohn's disease [J]. Journal of Parenteral And Enteral Nutrition, 1995, 19(2): 95-99.
[40]	Makhdoom ZA, Komar MJ, Still CD. Nutrition and enterocutaneous fistulas [J]. Journal of Clinical Gastroenterology, 2000, 31(3): 195-204.
[41]	Teubner A, Morrison K, Ravishankar HR, et al. Fistuloclysis can successfully replace parenteral feeding in the nutritional support of patients with enterocutaneous fistula [J]. British Journal of Surgery, 2004, 91(5): 625-631.
[42]	Buckman SA, Heise CP. Nutrition considerations surrounding restorative proctocolectomy [J]. Nutrition In Clinical Practice, 2010, 25(3): 250-256.
[43]	El Muhtaseb MS, Duncan A, Talwar DK, et al. Assessment of dietary intake and trace element status in patients with ileal pouch-anal anastomosis [J]. Diseases of the Colon & Rectum, 2007, 50(10): 1553-1557.
[44]	Montgomery SC, Williams CM, Maxwell PJt. Nutritional support of patient with inflammatory bowel disease [J]. Surgical Clinics of North America, 2015, 95(6): 1271-1279.
[45]	Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study [J]. Gastroenterology, 2005, 128(7): 1805-1811.
[46]	Ventham NT, Kalla R, Kennedy NA, et al. Predicting outcomes in acute severe ulcerative colitis [J]. Expert Review of Gastroenterology & Hepatology, 2015, 9(4): 405-415.
[47]	Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery [J]. American Journal of Gastroenterology, 2008, 103(9): 2373-2381.
[48]	Subramanian V, Pollok RC, Kang JY, et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators [J]. British Journal of Surgery, 2006, 93(7): 793-799.
[49]	Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults [J]. Gut, 2004, 53(Suppl 5): V1-16.
[50]	Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study [J]. Lancet, 2010, 375(9715): 657-663.
[51]	Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada [J]. Canadian Journal of Gastroenterology, 2007, 21(8): 507-511.
[52]	Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients [J]. American Journal of Gastroenterology, 2008, 103(9): 2272-2280.

Please choose a citation manager

Content to export